 Michael DiStefano
Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Negotiating | 5 | 2025 | 34 | 2.720 |
Why?
| | Morals | 4 | 2024 | 75 | 2.480 |
Why?
| | Medicare | 6 | 2025 | 799 | 2.470 |
Why?
| | Cost-Benefit Analysis | 8 | 2025 | 618 | 1.760 |
Why?
| | Technology Assessment, Biomedical | 6 | 2024 | 40 | 1.740 |
Why?
| | Direct-to-Consumer Advertising | 2 | 2024 | 7 | 1.670 |
Why?
| | Medicare Part D | 3 | 2023 | 25 | 1.620 |
Why?
| | Alzheimer Disease | 3 | 2024 | 583 | 1.510 |
Why?
| | Drug Costs | 6 | 2026 | 115 | 1.500 |
Why?
| | Prescription Drugs | 2 | 2023 | 115 | 1.320 |
Why?
| | Health Priorities | 3 | 2024 | 44 | 1.110 |
Why?
| | Health Facility Closure | 1 | 2025 | 9 | 0.950 |
Why?
| | Pharmacies | 1 | 2025 | 40 | 0.920 |
Why?
| | Community Pharmacy Services | 1 | 2025 | 49 | 0.910 |
Why?
| | Bioethics | 2 | 2024 | 20 | 0.880 |
Why?
| | Health Care Rationing | 1 | 2024 | 60 | 0.870 |
Why?
| | Comparative Effectiveness Research | 2 | 2025 | 164 | 0.840 |
Why?
| | Social Values | 2 | 2023 | 40 | 0.820 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 123 | 0.770 |
Why?
| | Medicare Part C | 1 | 2023 | 31 | 0.760 |
Why?
| | Drug Industry | 1 | 2023 | 110 | 0.720 |
Why?
| | Public Opinion | 1 | 2022 | 68 | 0.720 |
Why?
| | United States | 17 | 2026 | 15220 | 0.710 |
Why?
| | Health Equity | 1 | 2023 | 101 | 0.690 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 178 | 0.680 |
Why?
| | Qualitative Research | 2 | 2025 | 1516 | 0.640 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2024 | 697 | 0.590 |
Why?
| | Social Justice | 1 | 2019 | 79 | 0.580 |
Why?
| | Social Media | 1 | 2019 | 161 | 0.490 |
Why?
| | Wearable Electronic Devices | 1 | 2017 | 55 | 0.490 |
Why?
| | South Africa | 4 | 2023 | 240 | 0.450 |
Why?
| | Humans | 32 | 2026 | 141197 | 0.440 |
Why?
| | Blood Glucose | 1 | 2024 | 2269 | 0.440 |
Why?
| | Public Health | 1 | 2018 | 587 | 0.390 |
Why?
| | Policy | 2 | 2024 | 149 | 0.360 |
Why?
| | Aged | 10 | 2025 | 24576 | 0.350 |
Why?
| | Economics, Pharmaceutical | 2 | 2019 | 10 | 0.320 |
Why?
| | Depression | 1 | 2018 | 1483 | 0.290 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3776 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 852 | 0.270 |
Why?
| | Decision Making | 2 | 2024 | 961 | 0.250 |
Why?
| | Pharmacy Technicians | 1 | 2025 | 3 | 0.240 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1016 | 0.240 |
Why?
| | Costs and Cost Analysis | 2 | 2023 | 222 | 0.240 |
Why?
| | Genetic Therapy | 2 | 2025 | 315 | 0.240 |
Why?
| | Utah | 1 | 2025 | 65 | 0.240 |
Why?
| | Focus Groups | 2 | 2025 | 565 | 0.230 |
Why?
| | Biomedical Technology | 2 | 2022 | 50 | 0.230 |
Why?
| | Cost Savings | 1 | 2024 | 86 | 0.220 |
Why?
| | Reimbursement Mechanisms | 1 | 2025 | 83 | 0.220 |
Why?
| | Germany | 1 | 2024 | 132 | 0.210 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 113 | 0.210 |
Why?
| | Medicaid | 2 | 2025 | 451 | 0.210 |
Why?
| | Medicare Part B | 1 | 2023 | 4 | 0.210 |
Why?
| | Technology | 1 | 2024 | 94 | 0.200 |
Why?
| | National Health Programs | 1 | 2023 | 21 | 0.200 |
Why?
| | Hemophilia B | 1 | 2023 | 63 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 193 | 0.200 |
Why?
| | Pharmacists | 1 | 2025 | 263 | 0.190 |
Why?
| | Psychotherapy | 1 | 2024 | 184 | 0.190 |
Why?
| | Human Rights | 1 | 2022 | 20 | 0.190 |
Why?
| | Mental Competency | 1 | 2022 | 25 | 0.180 |
Why?
| | Hemophilia A | 1 | 2023 | 143 | 0.180 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 268 | 0.180 |
Why?
| | Health Expenditures | 1 | 2023 | 193 | 0.180 |
Why?
| | Drug Approval | 1 | 2022 | 92 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2025 | 267 | 0.170 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 212 | 0.170 |
Why?
| | Pressure Ulcer | 1 | 2021 | 45 | 0.170 |
Why?
| | Informed Consent | 1 | 2022 | 189 | 0.170 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2021 | 55 | 0.160 |
Why?
| | Patient Positioning | 1 | 2021 | 70 | 0.160 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5929 | 0.160 |
Why?
| | Patient Participation | 1 | 2024 | 432 | 0.160 |
Why?
| | Economic Competition | 1 | 2019 | 14 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2019 | 83 | 0.150 |
Why?
| | Female | 7 | 2025 | 75522 | 0.140 |
Why?
| | Civil Disorders | 1 | 2018 | 8 | 0.140 |
Why?
| | Public Health Surveillance | 1 | 2019 | 84 | 0.140 |
Why?
| | Colorado | 2 | 2025 | 4610 | 0.140 |
Why?
| | Adult | 4 | 2025 | 39181 | 0.140 |
Why?
| | Cell Phone | 1 | 2019 | 82 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2024 | 961 | 0.130 |
Why?
| | Retrospective Studies | 3 | 2024 | 16273 | 0.130 |
Why?
| | Research Design | 1 | 2024 | 1143 | 0.130 |
Why?
| | Diabetes Mellitus | 1 | 2026 | 1074 | 0.130 |
Why?
| | Male | 7 | 2025 | 69789 | 0.130 |
Why?
| | Developing Countries | 1 | 2019 | 317 | 0.130 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1123 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 857 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2026 | 1365 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2024 | 3348 | 0.120 |
Why?
| | Violence | 1 | 2018 | 276 | 0.110 |
Why?
| | Middle Aged | 3 | 2025 | 34438 | 0.110 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5636 | 0.100 |
Why?
| | Infant, Newborn | 1 | 2024 | 6275 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1816 | 0.100 |
Why?
| | Cohort Studies | 1 | 2023 | 5799 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2560 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 7070 | 0.090 |
Why?
| | Drugs, Generic | 1 | 2026 | 25 | 0.060 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2026 | 27 | 0.060 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2024 | 6 | 0.060 |
Why?
| | Markov Chains | 1 | 2025 | 126 | 0.060 |
Why?
| | Models, Economic | 1 | 2025 | 60 | 0.050 |
Why?
| | Ontario | 1 | 2019 | 95 | 0.040 |
Why?
| | Japan | 1 | 2019 | 133 | 0.040 |
Why?
| | Public Policy | 1 | 2019 | 82 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 696 | 0.030 |
Why?
| | Critical Care | 1 | 2021 | 649 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 7856 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11120 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 10438 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 13673 | 0.010 |
Why?
| | Child | 1 | 2022 | 22310 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22007 | 0.010 |
Why?
|
|
DiStefano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|